



Vimian Group comparative figures for 2020

The tables and figures presented below have not been audited or reviewed by the company's auditors.

Financial key ratios Q3 2020

EUR 000'	Specialty Pharma	Diagnostics	Veterinary Services	MedTech	Total Group
Revenue	-	5 483	3 814	11 501	20 799
Adjusted EBITA	(0)	1 741	1 442	4 541	7 724
Adjusted EBITA (%)	0,0%	31,7%	37,8%	39,5%	37,1%

Financial key ratios Q4 2020

EUR 000'	Specialty Pharma	Diagnostics	Veterinary Services	MedTech	Total group
Revenue	4 933	6 490	4 065	12 441	27 929
Adjusted EBITA	1 396	2 063	1 392	4 611	9 462
Adjusted EBITA (%)	28,3%	31,8%	34,2%	37,1%	33,9%

NOTE: Nextmune (Speciality Pharma) is only included from December 2020 as the company was consolidated in Vimian Group from December 2020 onwards.